Announcement of The Shaw Laureates 2025
HONG KONG, May 27, 2025 /CNW/ --
The Shaw Prize in Astronomy is awarded in equal shares to
John Richard Bond
Professor, Canadian Institute for Theoretical Astrophysics and University Professor, University of Toronto, Canada and
George Efstathiou
Professor of Astrophysics, University of Cambridge, United Kingdom
for their pioneering research in cosmology, in particular for their studies of fluctuations in the cosmic microwave background. Their predictions have been verified by an armada of ground-, balloon- and space-based instruments, leading to precise determinations of the age, geometry, and mass-energy content of the universe.
The Shaw Prize in Life Science and Medicine is awarded to
Wolfgang Baumeister
Director Emeritus and Scientific Member, Max Planck Institute of Biochemistry, Germany
for his pioneering development and use of cryogenic-electron tomography (cryo-ET), an imaging technique that enables three-dimensional visualisation of biological samples, including proteins, macromolecular complexes, and cellular compartments as they exist in their natural cellular settings.
The Shaw Prize in Mathematical Sciences is awarded to
Kenji Fukaya
Professor, Beijing Institute of Mathematical Sciences and Applications and the Yau Mathematical Sciences Center, Tsinghua University, PRC
for his pioneering work on symplectic geometry, especially for envisioning the existence of a category — nowadays called the Fukaya category — consisting of Lagrangians on a symplectic manifold, for leading the monumental task of constructing it, and for his subsequent ground-breaking and impactful contributions to symplectic topology, mirror symmetry, and gauge theory.
Tuesday, 27 May 202 5. At today's press conference in Hong Kong, The Shaw Prize Foundation announced the Shaw Laureates for 2025. Information was posted on the website www.shawprize.org at Hong Kong time 15:30 (GMT 07:30).
The Shaw Prize consists of three annual prizes: Astronomy, Life Science and Medicine, and Mathematical Sciences, each bearing a monetary award of US$1.2 million. This will be the twenty-second year that the Prize has been awarded and the presentation ceremony is scheduled for Tuesday, 21 October 2025 in Hong Kong.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a day ago
- Cision Canada
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy Français
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ - GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. "As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges," said Michelle Horn, Country Medical Director, GSK Canada. "Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred." Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. "As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries," said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. "PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally." Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. "Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare," added Michelle Horn, Country Medical Director, GSK Canada. "We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health." Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of Pharmacy The School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. SOURCE GlaxoSmithKline Inc.
Cision Canada
3 days ago
- Cision Canada
New Genomics Investments Expand eDNA Monitoring in BC's Remote and Indigenous Communities
VANCOUVER, BC, June 5, 2025 /CNW/ - On World Environment Day, Genome British Columbia (Genome BC) is proud to announce significant new investments that will expand Canada's capacity for environmental DNA or RNA (collectively called 'eDNA') monitoring. These investments highlight British Columbia's leadership in leveraging genomics to address pressing environmental and health challenges, particularly in remote and Indigenous communities. Nature's Fingerprints: eDNA is a New Tool that Reveals What's Living Around Us eDNA is a powerful tool that uses trace genetic material left behind in water, air and soil to detect pathogens, assess ecosystem health and support environmental decision-making. eDNA allows scientists and communities to detect and track species without needing to see them directly, offering a more efficient way to study ecosystems. eDNA can also track health and ecological signals without relying on invasive testing. This technology was widely used during the COVID-19 pandemic to monitor virus levels in wastewater and is now being expanded to keep people safe, protect biodiversity and help with climate resilience. The projects announced today focus on ensuring these tools are not just scientifically robust, but also community-driven and accessible — especially for regions with limited existing monitoring infrastructure. "These investments reflect how genomics is helping us learn directly from the environments we live in — and how that knowledge can be shared in ways that empower communities," said Federica Di Palma, Chief Scientific Officer and Vice President, Research and Innovation at Genome BC. "By supporting eDNA research rooted in partnership with Indigenous and remote communities, BC researchers are helping lead the way toward more inclusive, real-time approaches to health and environmental monitoring." Three Projects Expanding eDNA Use and Data Sharing The ChùNet and iMicroSeq projects are BC-based projects awarded through Genome Canada's eDNA Surveillance program, which includes a $11.3 million investment in 12 projects across the country aimed at building the scientific, technical and community capacity needed to scale eDNA surveillance. The eDNA Explorer Canada project is a separate initiative funded by Genome BC, though all three projects will coordinate their efforts. ChùNet: Enabling a knowledge sharing network — learning from water and the life it carries Led by: Erin Gill (Simon Fraser University) and Math'ieya Alatini (One Yukon Coalition) This project will establish a community-focused network to share data and knowledge about water-based eDNA monitoring in northern, rural, remote and Indigenous communities in BC and the Yukon. Co-led by academic and community partners, ChùNet will create tailored training resources and deploy a demonstration monitoring project while respecting OCAP® principles. The aim is to build a wholistic foundation for integrating environmental and public health surveillance that builds local priorities into decision making. iMicroSeq: Integrated, inclusive resources supporting environmental sequence data Led by: Fiona Brinkman and Emma Griffiths (Simon Fraser University) This project will develop a national data portal and communications platform that brings together researchers, Indigenous communities, public health officials and other in industry to support more coordinated, integrated microbial eDNA monitoring for wastewater and other water data. iMicroSeq will enhance data sharing, respect Indigenous data sovereignty (CARE and OCAP® Principles), and link human, agricultural and environmental health through a One Health lens. The platform will empower both community and industry innovation in economic, water-based pathogen detection and climate resilience. eDNA Explorer Canada: Upscaling eDNA Explorer to Enable Effective Biodiversity Monitoring in Canada Led by: Caren Helbing (University of Victoria) and Rachel Meyer (University of Santa Cruz & Chief Scientific Officer at eDNA Explorer) This project leverages the eDNA Explorer platform developed in California to create eDNA Explorer Canada. This powerful, easy-to-use portal will allow anyone to understand, evaluate and share eDNA data gathered in Canadian ecosystems, focusing on biodiversity monitoring, conservation and restoration. eDNA Explorer Canada is tailored to meet Canadian environmental standards and sovereignty needs, ensuring data is reliable and legally compliant. It aims to turn raw data into actionable insights that drive environmental protection efforts, building on existing relationships with Indigenous and government agencies established through the iTrackDNA project, which in 2021 and 2023 established Canada's national eDNA standards (learn more about those standards here). About Genome British Columbia: Genome BC is a not-for-profit organization that has advanced genomics research and innovation for 25 years, growing a world-class life sciences sector in BC and delivering sustainable benefits for British Columbia, Canada and beyond. Genome BC has attracted over $1 billion in direct co-investment to the province, which has contributed to funding more than 550 genomics research and innovation projects. These initiatives enhance healthcare and address environmental and natural resource challenges, improving the lives of British Columbians. Genome BC also integrates genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences among educators, students and the public.
Cision Canada
3 days ago
- Cision Canada
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /CNW/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
